United States · Series B startup

Who invested in NFlection Therapeutics

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$20Mraised across 1 round since 2022, from 1 source

Latest round
Series B, $20MJun 2022
Investors
1
See who backed them

The rounds

  1. Jun 2022
    Series B$20M

    Source recordedSEC filing: $10M sold, first sale Jun 2022

Founders and team

From NFlection Therapeutics's own website and the SEC filings it signed: 4 on the team.

  • William HodderChief Executive Officer
  • Guy WebsterVice President Clinical Operations
  • Diane MarcouChief Financial Officer
  • Patrice HorwathChief Development Officer

On the board, as filediChristopher PowalaCorey GoodmanJosh GrassKetan Patel

Everyone who backed them

Missing a round, or an investor who was in one? Tell us.

Quick answers about NFlection Therapeutics

Who invested in NFlection Therapeutics?

NFlection Therapeutics's investors include Eight Roads Ventures.

How much has NFlection Therapeutics raised?

NFlection Therapeutics has raised $20M across 1 round since 2022.

When did NFlection Therapeutics last raise?

NFlection Therapeutics's most recent round was a Series B of $20M in Jun 2022.

What was NFlection Therapeutics's biggest round?

Its most recent round, $20M in Jun 2022, is also its largest on record.

Who backed NFlection Therapeutics first?

NFlection Therapeutics's first round on record, in Jun 2022, was backed by Eight Roads Ventures.

What stage is NFlection Therapeutics at?

NFlection Therapeutics's latest named round is a Series B, in Jun 2022.

Where is NFlection Therapeutics based?

NFlection Therapeutics is based in the United States.

Companies like NFlection Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.